Another FDA failure as Lilly drug causes more deaths


When should the FDA pull a drug off the market? When one person dies from side-effects? How about two or three?

Eli Lilly (NYSE: LLY) and Amylin Pharmaceuticals (NASDAQ: AMLN) produce a highly successful diabetes drug called Byetta. According to The Wall Street Journal, "The Food and Drug Administration on Monday said it has received six new reports of patients developing a dangerous form of pancreatitis while taking Byetta."

Two of the patients died.

The drug makers said that the poor results were very rare. The people who got sick probably view it a little differently.

There have been questions for some time about whether the FDA does an effective job of regulating drug companies. The problems with Byetta say that the answer is "no." A drug, which causes even one death, yet stays on the market speaks volumes about how the consumer's interests are cast aside.

Douglas A. McIntyre is an editor at 247wallst.com.

Symbol Lookup
IndexesChangePrice
DJIA+57.4812,858.71
NASDAQ+22.952,926.83
S&P 500+7.471,350.11

Last updated: February 13, 2012: 10:10 AM

Hot Stocks

General Electric

18.955+0.08(+0.42)

Alcoa

10.42+0.13(+1.26)

Apple Inc

501.15+7.73(+1.57)

Google Inc 'A'

613.72+7.81(+1.29)

Bank of America

8.275+0.205(+2.54)

Wal-Mart Stores

61.92+0.02(+0.03)

Exxon Mobil Corp

84.06+0.26(+0.31)

Ford

12.63+0.19(+1.53)

Citigroup

33.54+0.615(+1.87)

IBM

192.77+0.35(+0.18)

Yahoo

16.175+0.035(+0.22)

Starbucks

48.98+0.16(+0.33)

Microsoft

30.695+0.20(+0.66)

Home Depot

45.69+0.36(+0.79)

DailyFinance Headlines

Benzinga Headlines

TheFlyOnTheWall.com Headlines

BioHealth Investor Headlines

WalletPop Headlines

DailyFinance BlackBerry App

My Portfolios

Track your stocks here!

Find out why more people track their portfolios on AOL Money & Finance then anywhere else.

BloggingStocks Partners

More from AOL Money & Finance

BioHealth Investor Headlines

Page Loaded in 1329145843212 ms.